MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases
Authors
Keywords
-
Journal
ADVANCES IN THERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-05-26
DOI
10.1007/s12325-022-02168-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impaired fertility in men diagnosed with inflammatory arthritis: results of a large multicentre study (iFAME-Fertility)
- (2021) Luis Fernando Perez-Garcia et al. ANNALS OF THE RHEUMATIC DISEASES
- Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
- (2021) Brian G Feagan et al. LANCET
- Sexual function and reproduction can be impaired in men with rheumatic diseases: A systematic review
- (2020) L.F. Perez-Garcia et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- The effect of paternal exposure to immunosuppressive drugs on sexual function, reproductive hormones, fertility, pregnancy and offspring outcomes: a systematic review
- (2020) L F Perez-Garcia et al. HUMAN REPRODUCTION UPDATE
- Filgotinib: First Approval
- (2020) Sohita Dhillon et al. DRUGS
- Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus
- (2019) Silvio Danese et al. DIGESTIVE DISEASES
- Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy
- (2019) Mark C. Genovese et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017
- (2019) Saeid Safiri et al. ANNALS OF THE RHEUMATIC DISEASES
- Chronic inflammation in the etiology of disease across the life span
- (2019) David Furman et al. NATURE MEDICINE
- The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2019) Sudabeh Alatab et al. Lancet Gastroenterology & Hepatology
- Evaluation of the Quality of Semen and Sexual Function in Men with Inflammatory Bowel Disease
- (2017) Paz Valer et al. INFLAMMATORY BOWEL DISEASES
- Frequency of and Factors Associated With Sexual Dysfunction in Patients With Inflammatory Bowel Disease
- (2017) P Rivière et al. Journal of Crohns & Colitis
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Ulcerative colitis
- (2017) Ryan Ungaro et al. LANCET
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- Current updates on laboratory techniques for the diagnosis of male reproductive failure
- (2016) SureshC Sikka et al. ASIAN JOURNAL OF ANDROLOGY
- Male fertility potential alteration in rheumatic diseases: a systematic review
- (2016) Bruno Camargo Tiseo et al. International Braz J Urol
- Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
- (2015) Florence Namour et al. CLINICAL PHARMACOKINETICS
- Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”
- (2015) Florence Namour CLINICAL PHARMACOKINETICS
- Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn’s disease
- (2015) Jason P. Gordon et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Sexual Dysfunctions in Men and Women with Inflammatory Bowel Disease
- (2015) Linda G.J. Bel et al. Journal of Sexual Medicine
- Limitations of semen analysis as a test of male fertility and anticipated needs from newer tests
- (2014) Christina Wang et al. FERTILITY AND STERILITY
- Semen analysis and prediction of natural conception
- (2014) Esther Leushuis et al. HUMAN REPRODUCTION
- Pregabalin Does Not Affect Sperm Production in Healthy Volunteers: A Randomized, Double-blind, Placebo-controlled, Noninferiority Study
- (2014) Suresh C. Sikka et al. Pain Practice
- Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease: a large cohort survey
- (2013) Míriam Mañosa et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Inflammatory bowel disease and pregnancy: Lack of knowledge is associated with negative views
- (2012) Christian P. Selinger et al. Journal of Crohns & Colitis
- Variability of Semen Parameters with Time in Placebo Treated Men
- (2012) Jonathan P. Jarow et al. JOURNAL OF UROLOGY
- Crohn's disease
- (2012) Daniel C Baumgart et al. LANCET
- World Health Organization reference values for human semen characteristics*‡
- (2009) Trevor G. Cooper et al. HUMAN REPRODUCTION UPDATE
- Fear and fertility in inflammatory bowel disease: A mismatch of perception and reality affects family planning decisions
- (2008) Réme Mountifield et al. INFLAMMATORY BOWEL DISEASES
- The Cycle of the Seminiferous Epithelium in Humans: A Need to Revisit?
- (2008) R. P. Amann JOURNAL OF ANDROLOGY
- An Evaluation of Semen Characteristics in Men 45 Years of Age or Older after Daily Dosing with Tadalafil 20mg: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, 9-Month Study
- (2007) Wayne J.G. Hellstrom et al. EUROPEAN UROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More